Indivior Pharmaceuticals, Inc.
INDV· Nasdaq
INDVIndivior Pharmaceuticals, Inc.
Filed Apr 30, 2026 · 10-Q · 30 days after period end · 0001628280-26-028850
| Metric | Q1 2026 | Q1 2025 | Q1 2024 |
|---|---|---|---|
| Revenue | $317.00M | $266.00M | $284.00M |
| Net Income | $89.00M | $47.00M | $61.00M |
| EPS Diluted | $0.69 | $0.38 | $0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Indivior Pharmaceuticals, Inc. · CIK 1625297 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed Apr 30, 2026 · 30 d after period end
